Last 48 quarters of trend data · Healthcare · Medical - Instruments & Supplies
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 40.97 | 16.08 | 47.38 | 23.21 | 23.55 | 13.00 | — | 49.24 | 20.94 | 56.92 | — | 798.48 | 80.33 | 120.38 | — | 217.00 | 87.38 | — | — | 212.88 | — |
| — | +23.7% | — | -52.9% | +12.5% | -77.2% | — | -93.8% | -73.9% | -52.7% | — | +268.0% | -8.1% | — | — | +1.9% | — | — | — | +2121.7% | — | |
| P/S Ratio | 1.79 | 1.37 | 1.43 | 1.30 | 1.50 | 0.91 | 0.82 | 1.35 | 1.03 | 1.10 | 1.42 | 1.80 | 1.64 | 1.64 | 1.33 | 1.61 | 1.37 | 1.83 | 1.89 | 3.54 | 2.52 |
| — | +49.8% | +74.9% | -3.8% | +46.3% | -17.1% | -42.4% | -24.9% | -37.4% | -32.9% | +6.8% | +12.1% | +19.4% | -10.6% | -29.5% | -54.6% | -45.5% | -60.3% | -58.7% | -14.2% | -8.7% | |
| P/B Ratio | 4.67 | 3.41 | 3.28 | 3.30 | 3.95 | 2.41 | 2.06 | 3.19 | 2.61 | 2.77 | 3.48 | 4.38 | 4.07 | 4.16 | 3.35 | 3.87 | 3.14 | 4.26 | 4.39 | 7.79 | 5.77 |
| — | +41.7% | +59.3% | +3.4% | +51.3% | -13.1% | -40.8% | -27.3% | -35.8% | -33.4% | +3.9% | +13.4% | +29.7% | -2.3% | -23.6% | -50.3% | -45.7% | -58.5% | -57.8% | -22.2% | -38.9% | |
| P/FCF | 16.30 | 6.03 | — | 11.23 | 7.42 | 5.70 | — | 16.25 | 5.64 | — | — | 21.55 | 19.88 | — | — | 90.48 | — | 32.58 | 52.11 | — | 82.15 |
| — | +5.9% | — | -30.9% | +31.6% | — | — | -24.6% | -71.6% | — | — | -76.2% | — | — | — | — | — | -4.5% | -91.7% | — | +497.4% | |
| EV / EBITDA | 10.17 | 13.59 | 11.02 | 6.70 | 8.56 | 5.66 | 9.22 | 8.75 | 6.92 | 9.58 | 26.32 | 15.02 | 12.88 | 14.27 | 16.26 | 13.45 | 10.72 | 16.34 | 20.75 | 19.61 | 22.29 |
| — | +140.1% | +19.5% | -23.5% | +23.7% | -40.9% | -64.9% | -41.7% | -46.2% | -32.9% | +61.8% | +11.6% | +20.1% | -12.7% | -21.6% | -31.4% | -51.9% | -42.4% | -23.2% | -18.8% | +93.1% | |
| EV / EBIT | 21.52 | 13.59 | 45.94 | 12.59 | 15.62 | 10.55 | 61.68 | 19.03 | 13.61 | 26.13 | — | 52.80 | 36.47 | 49.56 | — | 56.97 | 50.44 | 333.06 | — | 65.84 | — |
| — | +28.8% | -25.5% | -33.8% | +14.8% | -59.6% | — | -64.0% | -62.7% | -47.3% | — | -7.3% | -27.7% | -85.1% | — | -13.5% | — | +77.5% | — | -38.7% | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 56.0% | 58.0% | 58.4% | 56.4% | 57.1% | 55.2% | 55.2% | 53.8% | 53.9% | 49.5% | 51.5% | 49.3% | 48.9% | 49.9% | 49.2% | 55.8% | 59.5% | 55.1% | 57.4% | 57.7% | 57.4% |
| — | +5.0% | +5.8% | +4.8% | +5.8% | +11.6% | +7.2% | +9.2% | +10.2% | -0.9% | +4.6% | -11.6% | -17.7% | -9.5% | -14.3% | -3.4% | +3.5% | -9.1% | -3.6% | -4.8% | -4.6% | |
| Operating Margin | 8.3% | 11.2% | 4.7% | 10.3% | 10.4% | 10.5% | 1.8% | 7.7% | 9.2% | 5.5% | -2.6% | 3.9% | 5.3% | 3.9% | -0.4% | 3.6% | 3.5% | 0.8% | -2.0% | 6.0% | -1.3% |
| — | +7.2% | +165.2% | +32.6% | +13.0% | +90.6% | +167.4% | +96.4% | +73.8% | +40.0% | -649.6% | +10.2% | +53.8% | +413.7% | +82.0% | -40.9% | +361.6% | -72.7% | -155.0% | +44.2% | -110.2% | |
| Net Margin | 4.6% | 8.7% | 3.0% | 5.6% | 6.2% | 7.2% | -0.8% | 2.8% | 5.1% | 2.1% | -3.5% | 0.2% | 2.2% | 1.4% | -1.1% | 0.4% | 1.6% | -0.6% | -1.4% | 1.5% | -1.7% |
| — | +21.2% | +492.6% | +103.9% | +21.0% | +239.3% | +77.9% | +1116.4% | +136.9% | +55.2% | -225.8% | -38.9% | +33.0% | +326.0% | +22.4% | -74.6% | +196.3% | -118.4% | -150.9% | -96.6% | -114.4% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 11.5% | 5.5% | 1.8% | 3.6% | 4.1% | 4.7% | -0.5% | 1.7% | 3.3% | 1.4% | -2.1% | 0.1% | 1.4% | 0.9% | -0.7% | 0.2% | 0.9% | -0.4% | -0.8% | 0.8% | -1.0% |
| — | +15.7% | +469.8% | +118.7% | +23.9% | +249.5% | +77.7% | +1089.3% | +144.0% | +53.1% | -215.9% | -37.9% | +44.6% | +349.9% | +13.7% | -72.7% | +195.6% | -118.9% | -149.4% | -97.3% | -109.3% | |
| ROA | 6.5% | 3.3% | 1.0% | 2.0% | 2.3% | 2.5% | -0.3% | 0.9% | 1.7% | 0.7% | -1.1% | 0.1% | 0.7% | 0.4% | -0.3% | 0.1% | 0.4% | -0.2% | -0.4% | 0.4% | -0.5% |
| — | +29.9% | +497.4% | +128.6% | +33.8% | +277.1% | +76.0% | +1172.4% | +151.2% | +58.3% | -233.0% | -34.9% | +50.2% | +354.9% | +14.5% | -73.2% | +195.4% | -118.9% | -153.3% | -96.7% | -113.1% | |
| ROIC | 12.5% | 3.9% | 1.7% | 4.1% | 3.5% | 3.3% | 0.5% | 2.3% | 2.7% | 1.6% | -0.7% | 1.1% | 1.4% | 1.1% | -0.1% | 0.9% | 0.8% | 0.2% | -0.5% | 1.5% | -0.3% |
| — | +16.9% | +223.5% | +80.0% | +28.9% | +113.3% | +173.7% | +110.7% | +89.1% | +47.5% | -685.6% | +18.7% | +72.4% | +470.0% | +80.1% | -37.8% | +354.4% | -72.3% | -153.5% | +31.1% | -109.2% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.06 | 0.39 | 0.39 | 0.06 | 0.45 | 0.56 | 0.60 | 0.49 | 0.59 | 0.73 | 0.67 | 0.67 | 0.71 | 0.80 | 0.83 | 0.77 | 0.80 | 0.81 | 0.83 | 0.76 | 0.74 |
| — | -29.6% | -35.6% | -87.9% | -24.8% | -23.7% | -10.8% | -26.0% | -16.1% | -8.4% | -18.8% | -13.2% | -12.2% | -1.9% | -0.4% | +1.0% | +9.3% | +1.3% | -0.9% | -27.2% | -44.3% | |
| Debt / EBITDA | 0.14 | 5.64 | 4.70 | 0.49 | 3.48 | 4.28 | 8.42 | 4.71 | 5.13 | 8.01 | 17.16 | 7.94 | 7.62 | 9.20 | 12.94 | 8.93 | 8.77 | 10.51 | 13.28 | 6.99 | 10.09 |
| — | +31.7% | -44.2% | -89.7% | -32.1% | -46.6% | -50.9% | -40.7% | -32.8% | -12.9% | +32.6% | -11.1% | -13.1% | -12.5% | -2.6% | +27.7% | -13.0% | +27.2% | +63.2% | -25.1% | +76.9% | |
| Current Ratio | 1.80 | 2.50 | 2.14 | 1.80 | 1.90 | 2.19 | 2.21 | 1.82 | 1.98 | 2.07 | 1.87 | 1.95 | 2.08 | 2.22 | 2.00 | 1.71 | 1.86 | 1.59 | 1.67 | 1.71 | 1.51 |
| — | +14.0% | -3.3% | -1.1% | -4.2% | +5.9% | +18.0% | -6.5% | -4.7% | -6.8% | -6.5% | +13.8% | +12.1% | +39.8% | +20.1% | +0.1% | +23.0% | +16.4% | -13.6% | +32.2% | +38.8% | |
| Quick Ratio | 1.53 | 2.14 | 1.80 | 1.53 | 1.60 | 1.84 | 1.83 | 1.45 | 1.59 | 1.64 | 1.51 | 1.54 | 1.66 | 1.78 | 1.60 | 1.38 | 1.48 | 1.25 | 1.39 | 1.41 | 1.25 |
| — | +16.6% | -1.7% | +5.6% | +0.8% | +11.9% | +20.9% | -5.8% | -4.0% | -7.8% | -5.3% | +11.7% | +12.2% | +42.1% | +15.0% | -1.8% | +17.7% | +10.7% | -16.6% | +20.7% | +41.5% | |
| Interest Coverage | 9.18 | 16.18 | 4.56 | 14.45 | 8.42 | 10.24 | 1.75 | 7.69 | 6.85 | 3.70 | -1.85 | 2.49 | 2.99 | 2.02 | -0.29 | 2.29 | 2.42 | 0.56 | -2.00 | 3.35 | -1.46 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying INFU stock.
InfuSystem Holdings, Inc.'s current P/E is 41.0x. The average P/E over the last 4 quarters is 27.6x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
InfuSystem Holdings, Inc.'s current operating margin is 8.3%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking InfuSystem Holdings, Inc.'s business trajectory between earnings reports.